U.S., Dec. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07298343) titled 'Evaluating the Efficacy and Tolerability of ZED1227 in Subjects With Non-responsive Celiac Disease' on Dec. 17.
Brief Summary: A study to discover if ZED1227 can improve continued celiac disease symptoms despite a gluten-free diet
Study Start Date: June 10, 2024
Study Type: INTERVENTIONAL
Condition:
Celiac Disease
Intervention:
DRUG: ZED1227 + SIGE
oral treatment with different daily doses of ZED1227 vs placebo
OTHER: Placebo
Placebo + SIGE
Recruitment Status: ACTIVE_NOT_RECRUITING
Sponsor: Dr. Falk Pharma GmbH
Published by HT Digital Content Services with permission from Health Daily Digest....